Objective:To investigate the correlation between modified Glasgow prognostic score (mGPS) and prognosis of intrahepatic cholangiocarcinoma (ICC) patients after radical surgical resection.Methods:The clinical data of 126 patients with intrahepatic cholangiocarcinoma undergoing radical surgical resection at Ningbo Medical Centre Lihuili Hospital from Jan 2011 to Dec 2020 were retrospectively analyzed. The patients were scored according to the mGPS-related scoring standards, and the differences in tumor clinicopathological characteristics and prognosis were compared between patients with different score levels.Results:Firty-eight cases were included in group 0, 41 cases in group 1, and 27 cases in group 2. The 1- and 3-year survival rates in group 0 were 85.8% and 52.3%, the 1- and 3-year survival rates in group 1 were 73.2% and 23%, and the 1- and 3-year survival rates in group 2 were 73.3% and 0. The difference was statistically significant ( P<0.05). Univariate analysis showed that age, mGPS, CA19-9, tumor diameter, and tumor differentiation were related at the prognosis of ICC. Multivariate analysis showed that age, tumor differentiation, tumor diameter and mGPS were independent risk factors for the prognosis of ICC. Conclusion:mGPS is an independent risk factor affecting the prognosis of ICC patients.

BACKGROUND: Perioperative treatment has become an increasingly important aspect of the management of patients with non-small cell lung cancer (NSCLC). Small-scale clinical studies performed in recent years have shown improvements in the major pathological remission rate after neoadjuvant therapy, suggesting that it will soon become an important part of NSCLC treatment. Nevertheless, neoadjuvant immunotherapy may be accompanied by serious adverse reactions that lead to delay or cancelation of surgery, additional illness, and even death, and have therefore attracted much attention. The purpose of the clinical recommendations is to form a diagnosis and treatment plan suitable for the current domestic medical situation for the immune-related adverse event (irAE). METHODS: This recommendation is composed of experts in thoracic surgery, oncologists, thoracic medicine and irAE related departments (gastroenterology, respirology, cardiology, infectious medicine, hematology, endocrinology, rheumatology, neurology, dermatology, emergency section) to jointly complete the formulation. Experts make full reference to the irAE guidelines, large-scale clinical research data published by thoracic surgery, and the clinical experience of domestic doctors and publicly published cases, and repeated discussions in multiple disciplines to form this recommendation for perioperative irAE. RESULTS: This clinical recommendation covers the whole process of prevention, evaluation, examination, treatment and monitoring related to irAE, so as to guide the clinical work comprehensively and effectively. CONCLUSIONS Perioperative irAE management is an important part of immune perioperative treatment of lung cancer. With the continuous development of immune perioperative treatment, more research is needed in the future to optimize the diagnosis and treatment of perioperative irAE.